Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-11-13
pubmed:abstractText
Reports showing susceptibility of multidrug resistant (MDR) cancer cells to immune effectors, together with P-glycoprotein (P-gp) expression in immune effector subsets, including immature natural killer (NK) cells, and some activated T cells, suggest P-gp or some changes associated with it, have implications in immune-mediated mechanisms. A series of experiments were done to determine the nature of alterations associated with susceptibility to immune effector cells of MDR tumor cells. A cell line isolated from the malignant pleural effusion of a breast cancer patient was transfected with human and murine MDR1 genes, and four variants with different levels of MDR were obtained. Lymphokine-activated killer (LAK) activity was measured by a 51Chromium release, and conjugate formation assays. MDR1 transfectant P-gp+ breast carcinoma lines had increased LAK susceptibility compared to their parent line. Some part of the increased LAK susceptibility of drug-resistant cell lines was at the binding/recognition level as shown by conjugate formation assays. This suggests that differences may exist between paired cell lines with respect to the expression of cell adhesion molecules (CAMs). Monoclonal antibodies (mAbs) to CAMs and flow cytometry were used to quantitate these antigens. The CAMs studied were those previously found to be upregulated by stimulating NK cells with (interleukin-2) IL-2; ICAM-1 (CD54), LFA-3 (CD58), N-CAM (CD56), and the beta chain of LFA-1 (CD18). Although no differences in these CAMs were found between the breast carcinoma line and its MDR1-transfected variants, the target susceptibility results given above suggest that IL-2 treatment could be effective in combination with current protocols using chemotherapeutics, monoclonal antibodies (mAbs) and stem cell transplantation.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-10092063, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-10365150, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-10650785, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1454845, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-16236737, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-16236738, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-16236745, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-163658, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1673639, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1700001, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1706327, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1776860, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-1967244, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2180571, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2429319, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2458323, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2574987, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2785411, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-2819714, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3097239, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3258541, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3496283, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3670292, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3756908, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-3856953, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-46112, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-6176669, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-7298222, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-7317402, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-7334070, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-7647340, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-7678410, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-8946280, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-9256133, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-9626474, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-9831867, http://linkedlifedata.com/resource/pubmed/commentcorrection/17081316-9891492
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
1475-2867
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
24
pubmed:dateRevised
2009-11-18
pubmed:year
2006
pubmed:articleTitle
Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma.
pubmed:affiliation
Dept of Oncology, Akdeniz University, Antalya, Turkiye. savasb@akdeniz.edu.tr
pubmed:publicationType
Journal Article